contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


episurf-year-end-report-1-january-31-december-2024

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Episurf Medical operates in the medical technology industry and focuses on the development and manufacture of individually adapted implants for joint repair. The company's products are aimed at surgeons and healthcare institutions. The business is global with a main presence in Europe, North America and Asia. Episurf Medical was founded in 2008 and is headquartered in Stockholm, Sweden.

Episurf Medical

 Significant result and cash flow improvements Distribution agreement with Joint Operations for several European markets First sales through the Johnson & Johnson distributor network"We hereby...

<ul>	<li>Significant result and cash flow improvements</li>	<li>Distribution agreement with Joint Operations for several European markets</li>	<li>First sales through the Johnson &amp; Johnson distributor network</li></ul>"We hereby conclude the year 2024, a year in which we have made great progress. We have delivered on a significant part of our cost savings program. In the fourth quarter of 2024, we improved operating cash flow by SEK 7.6m to SEK -12.9m, a development I am very happy about. During 2024, we delivered on a substantial part of our cost reduction program, and we are now seeing a clearly improved trend, while also increasing sales and taking significant steps in the US. The first sale through Johnson &amp; Johnson's distributor network has now taken place, and in Europe we are taking a big step through our recently signed agreement with Joint Operations for several European countries. Finally, we believe that we are in the absolute final phase of our 510(k) process for our big toe implant in the US. All in all, there is a high level of activity, and we look forward to 2025 with confidence", says Pål Ryfors, CEO Episurf Medical.Fourth quarter 2024 compared to 2023, Group » Gross order intake amounted to SEK 3.1m (3.1) » Group net sales amounted to SEK 3.4m (3.0) » Order book amounted to SEK 2.4m (3.1) » Loss for the period amounted to SEK -18.1m (-21.9) » Earnings per share amounted to SEK -0.03 (-0.07)Twelve months 2024 compared to 2023, Group » Gross order intake amounted to SEK 13.0m (11.1) » Group net sales amounted to SEK 13.0m (10.3) » Loss for the year amounted to SEK -76.0m (-94.8) » Earnings per share amounted to SEK -0.15 (-0.30)Significant events during the fourth quarter 2024 » US VAC permissions granted for Episurf Medical » Seven new patent approvals for Episurf MedicalSignificant events during previous quarters 2024 » Results from up to 10 years follow-up of Episealer® patients were accepted for presentation » Episurf Medical has carried out a rights issue which incl. issue guarantees were subscribed to 75.0% and the company received SEK 90m before issue costs » Episurf Medical has entered into four distribution agreements with exclusive distributors of DePuy Synthes, the orthopaedic arm of the Johnson &amp; Johnson Group, for several US states » Update on 510(k) application for big toe implant » Niles Noblitt, through Sacajo Investments LLC, made investment in Episurf through an arrangement with CEO Pål Ryfors » Episealer® technology was presented at international scientific congressSignificant events after the quarter » Episurf Medical has announced that a response to the US FDA, addressing a request for additional information on the company's Episealer® MTP implant, has been filed » Episurf Medical enters into a distribution agreement for several European countries with Joint Operations Ltd<div></div>